U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06823596) titled 'The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY' on Dec. 03, 2024.
Brief Summary: Antiretroviral therapy or ART blocks HIV replication reducing plasma viral loads to undetectable levels but has no effect on persistently infected cells in the body, called the virus reservoir. These cells carry infectious HIV capable of restarting HIV replication if therapy is stopped. The reservoir is so stable forcing people to adhere life-long ART. Over 5% of ART adherent individuals continue to have residual non-suppressive viremia (NSV) detected by clinical assays (40-400 copies/ml). Residual viremia reflects a more persistent reservoi...